Suppr超能文献

使用电喷雾液相色谱/质谱法对小鼠血浆中的23-羟基白桦脂酸进行定量分析。

Quantitative analysis of 23-hydroxybetulinic acid in mouse plasma using electrospray liquid chromatography/mass spectrometry.

作者信息

Yang Min, Wang Guang Ji, Wang Su Jun, Li Xiao Tian, Xu Yu Ping, Wang Song Pei, Xiang Jing De, Pan Shang Ren, Cao Guo Xian, Ye Wen Cai

机构信息

Research Center of Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, P.R. China.

出版信息

Rapid Commun Mass Spectrom. 2005;19(12):1619-23. doi: 10.1002/rcm.1961.

Abstract

23-Hydroxybetulinic acid is a newly isolated derivative of betulinic acid. The agent exhibits potential anti-tumor activity and functions in this regard via apoptosis. In support of pharmacokinetic and toxicological evaluations, a new assay based on liquid chromatography/mass spectrometry (LC/MS) was developed for the quantitative analysis of 23-hydroxybetulinic acid. Sample preparation consisted of extraction of the plasma by the addition of methylene chloride followed by centrifugation. Aliquots of the supernatant were analyzed using an isocratic reversed-phase high-performance liquid chromatography (HPLC) system coupled to a negative ion electrospray mass spectrometer. Molecules of 23-hydroxybetulinic acid and the internal standard limonin were detected using selected ion monitoring at m/z 471 and 469, respectively. The limit of detection of 23-hydroxybetulinic acid was 0.05 pg (0.11 fmol) injected on-column (10 pg/mL, 5 microL injection volume), and the limit of quantitation was 10 pg (21.19 fmol, 2 ng/mL, 5 muL injection volume). 23-Hydroxybetulinic acid was stable in plasma samples at -20 degrees C for at least 3 weeks. The intra-day and inter-day coefficients of variation of the assay were 3.0 and 4.8%, respectively. The utility of the assay was demonstrated by measuring 23-hydroxybetulinicacid in mouse plasma following intragastric administration (IG) in vivo. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. A two-compartment, first-order model was selected for pharmacokinetic modeling. The result showed that after IG of 200 mg/kg 23-hydroxybetulinic acid, the plasma concentrations reached peaks at 2 h with C(max) of 3.1 microg/mL. The 200 mg/kg 23-hydroxybetulinic acid suspension IG doses were found to have long elimination half-lives of 25.6 h and low bioavailability of 2.3%. No interference was noted due to endogenous substances. These analytical methods should be of value in future studies related to the development and characterization of 23-hydroxybetulinic acid.

摘要

23-羟基桦木酸是一种新分离出的桦木酸衍生物。该药物具有潜在的抗肿瘤活性,并通过凋亡发挥这方面的作用。为支持药代动力学和毒理学评估,开发了一种基于液相色谱/质谱(LC/MS)的新方法用于23-羟基桦木酸的定量分析。样品制备包括加入二氯甲烷萃取血浆,然后离心。取上清液等分试样,使用与负离子电喷雾质谱仪联用的等度反相高效液相色谱(HPLC)系统进行分析。分别使用选择离子监测在m/z 471和469处检测23-羟基桦木酸和内标柠檬苦素的分子。23-羟基桦木酸的检测限为柱上进样0.05 pg(0.11 fmol)(进样体积5 μL,浓度10 pg/mL),定量限为10 pg(21.19 fmol,2 ng/mL,进样体积5 μL)。23-羟基桦木酸在-20℃的血浆样品中至少3周内稳定。该分析方法的日内和日间变异系数分别为3.0%和4.8%。通过在体内灌胃给药(IG)后测量小鼠血浆中的23-羟基桦木酸,证明了该分析方法的实用性。使用3P97药代动力学软件包计算药代动力学参数。选择二室一级模型进行药代动力学建模。结果表明,灌胃给予200 mg/kg 23-羟基桦木酸后,血浆浓度在2 h达到峰值,C(max)为3.1 μg/mL。发现200 mg/kg 23-羟基桦木酸悬浮液灌胃剂量具有25.6 h的长消除半衰期和2.3%的低生物利用度。未观察到内源性物质的干扰。这些分析方法在未来与23-羟基桦木酸的开发和特性研究相关的研究中应具有价值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验